Symposium 2-1. Circulating HBV Markers: What Are Their Roles?

Tarik Asselah (Hepatology at Hôpital Beaujon, France), Jung-Hwan Yoon (Seoul National Univ., Korea)

  • 08:30-08:50
  • Ultra-High Sensitivity HBsAg and Anti-HBc in Managing Chronic Hepatitis B

    Jihyun An (Hanyang Univ., Korea)

  • 08:50-09:10
  • HBcrAg and HBV RNA in Managing Chronic Hepatitis B

    Lung-Yi Mak (The Univ. of Hong Kong, Hong Kong)

  • 09:10-09:30
  • Circulating Virus-Host Chimera DNA for Monitoring Virus-Related HCC

    Shiou-Hwei Yeh (National Taiwan Univ., Taiwan)

  • 09:30-10:30
  • Plenary Session

  • 10:30-10:50
  • Coffee Break


Symposium 2-4. Direction to Pursue in Hepatitis C Treatment

Chun-Jen Liu (National Taiwan Univ., Taiwan), Seung Woon Paik (Sungkyunkwan Univ., Korea)

  • 10:50-11:05
  • How to Manage Patients with DAA Treatment Failure

    Young-Joo Jin (Inha Univ., Korea)

  • 11:05-11:20
  • How to Manage Difficult-to-Cure Patients: Decompensated Disease and Transplantation

    In Hee Kim (Jeonbuk National Univ., Korea)

  • 11:20-11:35
  • Managing Drug-Drug Interaction, Adherence, and Adverse Events in the Era of Pangenotypic DAA

    Woo Jin Chung (Keimyung Univ., Korea)

  • 11:35-11:50
  • Multidisciplinary Approach to Predict Fibrosis Progression and HCC after DAA Therapy

    Tawesak Tanwandee (Mahidol Univ., Thailand)

  • 11:50-12:50
  • Luncheon Symposium [Gilead] AGENDA


State-of-the-Art Lecture 2

Jin Mo Yang (The Catholic Univ. of Korea, Korea)

  • 12:50-13:20
  • The Road to Curing Hepatitis B Virus Infection: Past, Present, and Future

    George Lau (Humanity and Health Medical Group, Hong Kong)


Keynote Lecture 2. Cure of Viral Hepatitis. Is this Safe against the Development of HCC?

Jia-Horng Kao (National Taiwan Univ., Taiwan), Kyung-Suk Suh (Seoul National Univ., Korea)

  • 13:20-13:40
  • Genetic Polymorphism & Family History as a Non-Modifiable Risk Factor for HCC after HBV Cure

    Yoon Jun Kim (Seoul National Univ., Korea)

  • 13:40-14:00
  • Viral Persistence after a Functional Cure and HCC Risk

    Jia-Horng Kao (National Taiwan Univ., Taiwan)

  • 14:00-14:20
  • Mechanisms of Hepatocarcinogenesis after HCV Eradication

    Raymond T. Chung (Harvard Univ., USA)

  • 14:20-14:40
  • Coffee Break


APASL-AASLD Joint Session. A New Area of Interest in Chronic Hepatitis B: To Treat or Not to Treat

Norah Terrault (Univ. of Southern California, USA), Si Hyun Bae (The Catholic Univ. of Korea, Korea)

  • 14:40-15:00
  • Classification and Clinical Characteristics of Gray-Zone in Chronic Hepatitis B

    Marc G. Ghany (NIH, USA)

  • 15:00-15:20
  • HBeAg-Positive "Gray-Zone": Should We Treat and Why?

    Tai-Chung Tseng (National Taiwan Univ., Taiwan)

  • 15:20-15:40
  • HBeAg-Negative "Gray-Zone": Should We Treat and Why?

    Jordan Feld (Univ. of Toronto, Canada)

  • 15:40-16:00
  • Optimizing Non-Invasive Methods to Identify Gray-Zone Patients with Liver Fibrosis

    Seung Up Kim (Yonsei Univ., Korea)

  • 16:00-16:20
  • Coffee Break


Symposium 2-7. Debate Session. Strategies to Achieve HBsAg Seroclearance

W. Ray Kim (Stanford Univ., USA), Maria Buti Ferret (Hospital Universitario Valle Hebron, Spain)

  • 16:20-16:35
  • Stopping Antivirals

    Wen-Juei Jeng (Chang Gung Univ., Taiwan)

  • 16:35-16:50
  • Continuing Antivirals

    Jonggi Choi (Ulsan Univ., Korea)

  • 16:50-17:05
  • Interferon or Interferon-Based Therapy

    Tarik Asselah (Hepatology at Hôpital Beaujon, France)

  • 17:05-17:20
  • Newer Antiviral Agents: Next Steps to Combination Therapy

    Robert G. Gish (Hepatitis B Foundation, USA)

  • 17:20-17:40
  • Panel Discussion


Symposium 2-2. Update of Cirrhosis and Portal Hypertension

Shiv Kumar Sarin (Institute of Liver & Biliary Sciences, India), Dong Joon Kim (Hallym Univ., Korea)

  • 08:30-08:45
  • Liver and Spleen Stiffness for the Estimation of Portal Hypertension and Cirrhotic Complications

    Moonyoung Kim (Yonsei Univ. Wonju, Korea)

  • 08:45-09:00
  • Antiviral Therapy and the Outcome of Patients with Decompensated Cirrhosis

    Sung Eun Kim (Hallym Univ., Korea)

  • 09:00-09:15
  • Optimal Assessment and Improving Survival in Acute Variceal Bleeding

    Shiv Kumar Sarin (Institute of Liver & Biliary Sciences, India)

  • 09:15-09:30
  • The Role of Antibiotic Therapy in Acute Decompensation

    Jung Gil Park (Yeungnam Univ., Korea)


Symposium 2-3. Non-B Non-C Viral Hepatitis: Pathogenesis and Treatment

Jaeseok Hwang (Keimyung Univ., Korea), Hee Bok Chae (Chungbuk National Univ., Korea)

  • 09:30-09:45
  • Immunopathogenesis of Acute Hepatitis A

    Eui-Cheol Shin (KAIST, Korea)

  • 09:45-10:00
  • Novel Therapies for Hepatitis D virus

    Young Eun Chon (CHA Univ., Korea)

  • 10:00-10:15
  • Disease Burden and Potential Therapeutic Approach to HEV Infection

    Lubna Kamani (Liaquat National Hospital, Pakistan)

  • 10:15-10:30
  • Pathogenesis and Management of Non-Hepatotropic Viruses

    Ju-Yeon Cho (Chosun Univ., Korea)

  • 10:30-10:50
  • Coffee Break


Symposium 2-5. Metabolic Disease and Viral Hepatitis

Jose D. Sollano (The Univ. of Santo Tomas, Philippines), Sang Hoon Park (Hallym Univ., Korea), Oh Sang Kwon (Gachon Univ., Korea)

  • 10:50-11:05
  • Role of Metabolic Risk Factors in the Outcome of Viral Hepatitis

    Lai Wei (Tsinghua Univ., China)

  • 11:05-11:20
  • Effects of Alcohol Drinking on the Prognosis of Patients with Viral Hepatitis

    Won Kim (Seoul National Univ., Korea)

  • 11:20-11:35
  • MAFLD in Chronic Hepatitis B: Friend or Foe?

    Lung-Yi Mak (The Univ. of Hong Kong, Hong Kong)

  • 11:35-11:50
  • Management Strategies for Viral Hepatitis with Concurrent MAFLD

    Hye Won Lee (Yonsei Univ., Korea)

  • 11:50-12:50
  • Luncheon Symposium [Yuhan] AGENDA

  • 14:20-14:40
  • Coffee Break


Symposium 2-6. Prevention and Surveillance of Viral Hepatitis-Associated HCC

Shuichiro Shiina (Juntendo Univ., Japan), Joong-Won Park (National Cancer Center, Korea), Jong Young Choi (The Catholic Univ. of Korea, Korea)

  • 14:40-15:00
  • Anti-HBV Therapy to Prevent HBV-Associated HCC

    Tetsuya Hosaka (Toranomon Hospital, Japan)

  • 15:00-15:20
  • Anti-HCV Therapy to Prevent HCV-Associated HCC

    Do Young Kim (Yonsei Univ., Korea)

  • 15:20-15:40
  • Non-Viral Managements to Prevent HCC

    Dong Hyun Sinn (Sungkyunkwan Univ., Korea)

  • 15:40-16:00
  • Risk-Stratified Surveillance for Hepatitis Virus-Associated HCC

    Shuichiro Shiina (Juntendo Univ., Japan)

  • 16:00-16:20
  • Coffee Break


Symposium 2-8. AI & Machine Learning for Liver Disease Management

Moon Seok Choi (Sungkyunkwan Univ., Korea), Il Han Song (Dankook Univ., Korea)

  • 16:20-16:40
  • Developing AI Model for Predicting HCC

    Hwi Young Kim (Ewha Womans Univ., Korea)

  • 16:40-17:00
  • Radiomics and Deep Learning for Chronic Liver Disease

    Roongruedee Chaiteerakij (Chulalongkorn Univ., Thailand)

  • 17:00-17:20
  • Harnessing Knowledge and Experimental Data Using AI Drug Discovery Technology

    Han Jo Kim (Standigm, Korea)

  • 17:20-17:40
  • Deep Learning-Based Prediction of Biomarkers Using Liver Cancer Histopathological Images

    Sung Hak Lee (The Catholic Univ. of Korea, Korea)


Early Morning Workshop 1. Emerging Risk Factors of HCC in Chronic Hepatitis B

Diana A. Payawal (Fatima Medical Univ., Philippines)

  • 07:30-07:42
  • Impact of Metabolic Factors on the Risk of HBV-Related HCC

    Yun Bin Lee (Seoul National Univ., Korea)

  • 07:42-07:54
  • Have Risk Factors for HCC Changed over the Decades?

    Roongruedee Chaiteerakij (Chulalongkorn Univ., Thailand)

  • 07:54-08:20
  • Discussion

    Discussants: Yun Bin Lee (Seoul National Univ., Korea), Roongruedee Chaiteerakij (Chulalongkorn Univ., Thailand), Kang Mo Kim (Univ. of Ulsan, Korea), Tai-Chung Tseng (National Taiwan Univ., Taiwan)


SIG 2. cccDNA and HBV Integration: Stumbling Blocks for HBV Cure

Byung-Cheol Song (Jeju Univ., Korea), Kyun-Hwan Kim (Sungkyunkwan Univ., Korea)

  • 09:30-09:50
  • HBV cccDNA: Mechanism of Its Formation and Therapeutic Targets

    Kyun-Hwan Kim (Sungkyunkwan Univ., Korea)

  • 09:50-10:10
  • HBV Integration and Liver Cancer

    Thomas Tu (Westmead Institute for Medical Research, Australia)

  • 10:10-10:30
  • Genome Editing for cccDNA and Integrated HBV

    Jae Young Lee (ToolGen, Korea)


SIG 3. Immunopathogenesis of Viral Hepatitis

Jeong Heo (Pusan National Univ., Korea), Eui-Cheol Shin (KAIST, Korea)

  • 10:50-11:05
  • Type I and Type III Interferon Responses in Hepatitis Virus Infection

    Pil Soo Sung (The Catholic Univ. of Korea, Korea)

  • 11:05-11:20
  • T-Cell Responses and Immunopathogenesis of Chronic Hepatitis B

    Yuri Cho (National Cancer Center, Korea)

  • 11:20-11:35
  • Characteristics of B-Cells in HBV-Associated Chronic Liver Disease

    Ji Eun Oh (KAIST, Korea)

  • 11:35-11:50
  • Chronic Hepatitis and Liver Fibrosis in Humans

    Hideki Ueno (Kyoto Univ., Japan)

  • 11:50-12:50
  • Luncheon Symposium [Daewoong] AGENDA


Hepatology Associates - Education Forum 1. Approach to Various Chronic Liver Disease (*K)

Tae Hun Kim (Ewha Womans Univ., Korea), Jung Woo Shin (Univ. of Ulsan, Korea)

  • 13:20-13:35
  • Treatment of Chronic Hepatitis B: When and Whom?

    Jae Yoon Jeong (National Medical Center, Korea)

  • 13:35-13:50
  • Diagnosis and Management of Hepatitis C Virus Infection

    Woo Sun Rou (Chungnam National Univ.)

  • 13:50-14:05
  • Diagnosis and Management of Autoimmune Hepatitis

    Young Chang (Soonchunhyang Univ., Korea)

  • 14:05-14:20
  • Surveillance and Diagnosis of HCC

    Han Ah Lee (Ewha Womans Univ., Korea)

  • 14:20-14:40
  • Coffee Break


Hepatology Associates - Education Forum 2. Metabolism, Alcohol and Toxicity (*K)

Byung Seok Lee (Chungnam National Univ., Korea), Gab Jin Cheon (Univ. of Ulsan, Korea)

  • 14:40-15:00
  • Epidemiology, Natural History and Risk Stratification of NAFLD

    Yang-Hyun Baek (Dong-A Univ., Korea)

  • 15:00-15:20
  • Lifestyle Intervention and Available Medications in NAFLD Treatment

    Se Young Jang (Kyungpook National Univ., Korea)

  • 15:20-15:40
  • Management of Severe Alcoholic Hepatitis

    Tae Suk Kim (Kangwon National Univ., Korea)

  • 15:40-16:00
  • Updated Guideline on Drug-Induced Liver Injury

    Nae-Yun Heo (Inje Univ., Korea)

  • 16:00-16:20
  • Coffee Break


Hepatology Associates - Education Forum 3. Cirrhosis and Complications, Case-Based Learning (*K)

Chang Hyeong Lee (Daegu Catholic Univ., Korea), Young Seok Kim(Soonchunhyang Univ., Korea)

  • 16:20-16:35
  • Diagnosis and Management of Ascites and Related Complications

    Chang Hun Lee (Jeonbuk National Univ., Korea)

  • 116:35-16:50
  • Diagnosis and Management of Acute Variceal Bleeding

    Seong Hee Kang (Korea Univ., Korea)

  • 16:50-17:05
  • When Is the Appropriate Time for Liver Transplantation?

    Kwang Il Seo (Kosin Univ., Korea)

  • 17:05-17:20
  • Treatment Strategy Based on HCC Stage

    Jung Hwan Yu (Inha Univ., Korea)


Early Morning Workshop 2. Real-Life Experiences in HCV Management

Ming-Lung Yu (National Sun Yat-sen Univ., Taiwan)

  • 07:30-07:42
  • Are Metabolic Derangements Corrected after Cure of HCV?

    Eun Ju Cho (Seoul National Univ., Korea)

  • 07:42-07:54
  • Effects of DAA Treatment on Extrahepatic Manifestations in HCV Infection

    Hyun Phil Shin (Kyung Hee Univ., Korea)

  • 07:54-08:20
  • Discussion

    Discussants: Eun Ju Cho (Seoul National Univ., Korea), Hyun Phil Shin (Kyung Hee Univ., Korea), Tetsuya Hosaka (Toranomon Hospital, Japan), Geum-Youn Gwak (Sungkyunkwan Univ., Korea)